Search Our Genitourinary Cancer Clinical Trials


The Cancer Center at BIDMC is an important center of research into the safety and effectiveness of new cancer therapies. Your physician will help you evaluate whether participation in a clinical trial is appropriate for you.

The following clinical trials related to prostate cancer, bladder cancer and other genitourinary cancers are now available through BIDMC. Please email or call Arline Broberg at 617-975-7403 if you have questions about participating in clinical trials.

  • A phase II study of nivolumab combined with ipilimumab for patients with advanced rare genitou-rinary tumors - Learn More.

  • A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer - Learn More.

  • A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer - Learn More.

  • A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration-Resistant Pros-tate Cancer and DNA-Repair Anomalies - Learn More.

  • Phase IB Trial of Radium-223 and Niraparib in Patients with Castrate Resistant Prostate Can-cer - Learn More.

  • A Phase 2 Study of PCM-075 in Combination with Abiraterone and Prednisone in Subjects with Metastatic Castration-Resistant Prostate Cancer - Learn More.

  • "A Phase 2 Study of Nivolumab in Patients with High-Risk Biochemically Recurrent Prostate Can-cer" - Learn More.

  • Phase II randomized study of neoadjuvant and adjuvant abiraterone acetate + apalutamide for intermediate-high risk prostate cancer undergoing prostatectomy. - Learn More.

  • A Randomized, Phase II Study Evaluating the Addition of Pembrolizumab (MK-3475) to Radium-223 in Metastatic Castration Resistant Prostate Cancer (mCRPC). - Learn More.

  • Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone Acetate and Apalutamide (ARN-509) for Rising PSA after Radical Prostatectomy with Adverse Features. Facilitating Optimal Radiation Management Using Leuprolide, Abiraterone Acetate, and Apalutamide (FORMULA-509 Trial)  - Learn More.

  • Prostvac in Patients with Biochemical Recurrent Prostate Cancer  - Learn More.

  • A Randomized Phase 2 Study of cediranib in Combination with olaparib versus olaparib alone in men with metastatic castration resistant prostate cancer - Learn More.

  • Phase I Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, A C-MET/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer. - Learn More.

  • A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination with Nivolumab in Patients with Advanced/Metastatic Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer - Learn More.

  • A PHASE 1, DOSE-ESCALATION AND EXPANSION TRIAL OF PT2977, A HIF-2á INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS - Learn More.

Updated November 2018.


Prostate Cancer Clinical Trials

  • Phase II randomized study of neoadjuvant and adjuvant abiraterone acetate + apalutamide for intermediate-high risk prostate cancer undergoing prostatectomy. - Learn More.

  • A Randomized, Phase II Study Evaluating the Addition of Pembrolizumab (MK-3475) to Radium-223 in Metastatic Castration Resistant Prostate Cancer (mCRPC). - Learn More.

  • Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone Acetate and Apalutamide (ARN-509) for Rising PSA after Radical Prostatectomy with Adverse Features. Facilitating Optimal Radiation Management Using Leuprolide, Abiraterone Acetate, and Apalutamide (FORMULA-509 Trial)  - Learn More.

  • Prostvac in Patients with Biochemical Recurrent Prostate Cancer  - Learn More.

  • A Randomized Phase 2 Study of cediranib in Combination with olaparib versus olaparib alone in men with metastatic castration resistant prostate cancer - Learn More.

  • Phase II randomized study of neoadjuvant and adjuvant abiraterone acetate + apalutamide for intermediate-high risk prostate cancer undergoing prostatectomy. - Learn More.

  • A Randomized, Phase II Study Evaluating the Addition of Pembrolizumab (MK-3475) to Radium-223 in Metastatic Castration Resistant Prostate Cancer (mCRPC). - Learn More.

  • Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone Acetate and Apalutamide (ARN-509) for Rising PSA after Radical Prostatectomy with Adverse Features. Facilitating Optimal Radiation Management Using Leuprolide, Abiraterone Acetate, and Apalutamide (FORMULA-509 Trial)  - Learn More.

  • Prostvac in Patients with Biochemical Recurrent Prostate Cancer  - Learn More.

  • A Randomized Phase 2 Study of cediranib in Combination with olaparib versus olaparib alone in men with metastatic castration resistant prostate cancer - Learn More.

Updated November 2018.

Back to top